Background {#Sec1}
==========

The global burden of cancer is on the rise in the middle and low economic countries accounting for 82% of total cancer population and 70% of cancer related deaths worldwide \[[@CR1], [@CR2]\]. The rise has been attributed to improved management of communicable diseases, thereby, leading to increasing aging population and incidence of non-communicable diseases. Besides this, rapid urbanization has further assisted in escalating prevalence of established risk factors like physical inactivity, obesity, pollution and changing reproductive patterns \[[@CR1]\]. World Health Organization (WHO) defines Palliative care as "an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual" \[[@CR3]\]. In spite of massive demands of palliation and hospices, palliative care physicians and centers are few and far between in our country \[[@CR4]\].

Cancer palliative patients present with a number of symptoms secondary to the primary disease including pain, dyspnea, lethargy, easy fatigability and personal feeling of being unwell. Anemia is the most frequently encountered clinical finding needing prudent attention in cancer palliative patients, believed to cause a majority of symptoms. In cancer, several cytokines namely tumor necrosis factor -α (TNF-α), transforming growth factor -β (TGF-β), interleukin-1 (IL-1), IL-6 and interferon-γ interfere normal erythrocyte production by modulating iron metabolism and blunting erythropoietin effect thereby causing anemia \[[@CR5]\]. Cancer Induced Anemia (CIA) \[[@CR6]\] is associated with a decline in patients performance status, cognitive function, decreased quality of life (QoL) and overall survival, therefore, correction of anemia is likely to improve survival benefits \[[@CR7]\]. Anemia can be treated using blood transfusions, iron and vitamin B12 supplementation and use of erythropoiesis-stimulating agents (ESA) \[[@CR8]\]. Correction of anemia in palliative settings using blood transfusion could be beneficial as it has rapid response to anemia induced symptoms. However, this does not mean the treatment of anemia should only be restricted to blood transfusion. As blood products are scarce resources it should be used vigilantly and dogmatically. Studies on beneficial effects of transfusion in cancer palliative patients are highly inconclusive, and blood transfusion is highly individualized \[[@CR9]\]. Rather than being dictated by hemoglobin (Hb) values, transfusion of blood products should be aimed at improving the functional status and QoL \[[@CR10]--[@CR13]\]. Hemoglobin is the most widely accepted standard transfusion trigger in all anemic patients and is usually based on subjective symptoms of easy fatigability, shortness of breath and lethargy \[[@CR14]\]. In absence of any cardiac disease, the recommended hemoglobin value for restricted packed red cell transfusion is 7-9 g/dL and is 10-12 g/dL for liberal transfusion \[[@CR15]\]. No standard guidelines can be found in the literature regarding transfusion in palliative patients. Some studies have shown beneficial effects of transfusion immediately after transfusion but wearing off after 2 weeks, while other studies fail to report any benefits \[[@CR16], [@CR17]\].

Cancer Related Fatigue (CRF) is a subjective feeling of persistent distress, tiredness, or exhaustion related to cancer or cancer related treatments that would otherwise not interfere with normal functioning \[[@CR18]\]. CRF is multifactorial with pro-inflammatory cytokines, IL-1, metabolic and insulin insensitivity as most commonly proposed causes \[[@CR19]\]. It has been reported to be as high as 90% in cancer patients. Anemia is the most common reversible cause of CRF in cancer palliative patients and correction of anemia can improve the symptoms of fatigue. The current study aims at evaluating the changes in subjective symptoms of fatigue and breathlessness in transfused and non-transfused cancer palliative patients.

Methods {#Sec2}
=======

This was a hospital-based longitudinal study conducted from July to December 2017 at Nepal Cancer Hospital and Research Center, Harishiddi, Lalitpur (1400 m above sea level). Ethical clearance for the study was obtained from IRC-NCHRC. The study included a total of 122 cancer palliative patients both admitted to the hospital and attending palliative OPD. Information about the type of cancer, stage and site was not recorded. A written consent was obtained from all the patients for participation in the study. Patients with advanced cancer on diagnosis (Stage IIIb and IV), progressive and refractory or recurrent to chemotherapy and those who did not accept any form of active-cancer treatment either due to religious, social or economic reasons were included in the study. Patients receiving active cancer treatment; chemotherapy or radiotherapy and those with hematological malignancies were not included in the study. Patients with hematological malignancies both actively receiving chemotherapy and those in remission followed up with either oncologists or hematologists, so these groups of patients were not included in the present study. Also, patients who had have transfusions within the past 3 months and those who received ESA within the past 2 months were also excluded from the study. Participants were evaluated for subjective symptoms of fatigue and breathlessness. Fatigue was categorized with the subjective response as "yes" or "no" answers and evaluation of breathlessness was done using the Dyspnea Index (DI) and was categorized as very severe (0) to no breathlessness (4). Hemoglobin values were obtained from the laboratory using automatic hematology analyzers. Appropriate internal quality controls were run before assay of the sample. Packed red cell (350 ml) transfusion was ordered for hemoglobin values less than 10 g/dL and subjective symptom of fatigue and breathlessness. Every unit of packed red cell (350 ml) transfused was expected to raise the hemoglobin levels by 1 g/dL and follow-up hemoglobin level was targeted at a value above 10 g/dL. Both the group of patients (transfused vs. non-transfused) were reevaluated on day 7 and reassessed for subjective symptoms of fatigue and breathlessness and the response was noted accordingly. Statistical analysis was done using the program SPSS version 20. Hemoglobin values less than 10 g/dL was considered as anemic. The numerical values were expressed as mean ± SD and categorical variables as percentage. McNemar's test was done to evaluate the difference in fatigue and dyspnea score pre and post-transfusion.

Results {#Sec3}
=======

A total of 136 patients attended the palliative care ward and OPD during the course of the study. Six of them did not agree to participate in the study due to social or religious reasons, 5 of them did not fit the inclusion criteria and 3 of them could not be followed up (1 passed away and 2 were unreachable). Of the remaining 122 patients in the study, 63(51.6%) were males and 59(48.4%) were females. The median age was 60 years (range 13--88 years). The mean age was 55.32 ± 16.79 years with 61.5% (75/122) of patients above 50 years.

The mean hemoglobin concentration was 10.53 ± 1.51 g/dL. Of the 122 patients in the study 44(36.1%) were anemic and 78(63.9%) of the patients were non-anemic. Table [1](#Tab1){ref-type="table"} shows the mean hemoglobin concentration of anemic and non-anemic participants in the study along with number of anemic and non-anemic patients with symptoms of fatigue and breathlessness.Table 1Variables in anemic and non-anemic study groupAnemicNon-anemicNo of patients44 (36.1%)78(63.9%)Mean Hb g/dL9.03 ± 0.7211.38 ± 1.14Fatigue36/4434/78Breathlessness32/443/78

All 44 anemic patients with Hb \< 10 g/dL were transfused packed red blood cell irrespective of symptoms. Also, 2 patients with Hb \> 10 g/dL but with symptoms of breathlessness underwent transfusion. A total of 46 patients received 64 pints of packed red cell transfusion during the course of the study with an average transfusion rate of 1.36 ± 0.67 pints. The lowest hemoglobin level for which packed cell was transfused was 7.1 g/dL and the highest was 10.4 g//dL. Of the total transfusion, 32 of the patients received 1 pint, 10 of them received 2 pints and 4 of them received 3 pints of packed red cell transfusion. The primary transfusion indication was low hemoglobin concentration and/or symptoms of fatigue or breathlessness.

Table [2](#Tab2){ref-type="table"} compares the symptoms of breathlessness and fatigue among transfused and non-transfused palliative patients.Table 2Comparison of fatigue and breathlessness symptoms among transfused (2A) and non-transfused patients (2B) pre and post transfusion2APacked cell Transfusion Status*p* value*n* = 46Pre-TransfusionPost-TransfusionFatigue37 (80.4%)20 (43.4%)\< 0.001Breathlessness35 (76.0%)9 (19.5%)\< 0.0012B *n* = 76Packed cell not transfusedp valueBeforeAfterFatigue33 (43.4%)22 (28.9%)\< 0.05Breathlessness00--

70 (57.4%) of the total patients presented with complaints of fatigue and 35 (28.7%) with breathlessness. Prior to transfusion, 80.4% (37/46) patients had fatigue, but only 43.4% of them complained of fatigue post-transfusion. Likewise, improvement in breathlessness symptom was noted in 56.4% of patients post-transfusion. Symptom relief was found to be statistically significant in packed cell transfused patients (*p* \< 0.001).

In patients who did not receive transfusion, there was a 14.5% reduction in fatigue on follow up after 7 days. The improvement in fatigue score was also statistically significant in non-transfused group (*p* \< 0.05). Among the non-transfused group of patients, none of the patients had breathlessness on presentation at both times.

Early transfusion reactions like thrombophlebitis 2.1% (1/46) and non-hemolytic febrile reactions 10.8% (5/46) was noted.

Discussion {#Sec4}
==========

Anemia in palliative patients can be a result of global impact of cancer on bone marrow which can occur even before any anticancer treatment. Cytokines like TNF-α blunts erythropoietin effect and IL-1, IL-6 and interferon-γ interfere with iron metabolism causing anemia. Chronic inflammation, malnutrition, bleeding, renal insufficiency, anemia of chronic disease and other co-morbidities have been attributed as a cause of anemia in cancer patients \[[@CR20]\]. Anemia in cancer palliative patients in the present study was estimated at 36.1% similar to Ludwig H. et al. \[[@CR21]\] while others have reported prevalence as high as 65% \[[@CR20]\]. Maccio A. et al. \[[@CR20]\] reported a higher percentage of CIA in advanced cases and compromised performance status (PS) but the present study did not categorize the severity of cases and PS.

Blood transfusion is useful in the management of anemia in palliative patients, especially when anemia in cancer patients decreases the functional status and QoL. The transfusion rate was 37.7% which was slightly higher than previous studies \[[@CR8], [@CR21]--[@CR23]\]. Moreover, several studies have observed that palliative patients at the end of their life are more likely to receive additional transfusions than normal setting \[[@CR23]--[@CR25]\].

The currently practiced hemoglobin trigger for packed cell transfusion was \< 10 g/dL, atypical of the internationally recommended value of \< 9 g/dL \[[@CR8], [@CR26]\], nonetheless subgroups of breast cancer patients have shown survival benefits when transfused at Hb \< 10.5 \[[@CR27]\]. Due to the lack of expert palliative care manpower in the country, practicing oncologists are added with extra burden working as palliative care physicians. Oncologists' priority of chemotherapy over palliative care and a lack of adequate palliative care expertise could yet be another factor influencing transfusion rates. Also, liberal transfusion of Hb \< 10 g/dL, over restrictive transfusion of Hb \< 7gdL was practiced in the institute. However, no studies have yet been conducted as to identify which groups of patients are likely to benefit most from transfusion \[[@CR16], [@CR28]\]. In normal 70 kg adult, one unit of packed red blood cells should increase the levels of hemoglobin by 1 g/dL and hematocrit by 3% \[[@CR29]\]. We believe that altitude has nothing to do with the liberal transfusion strategy currently adopted at this center.

In spite of blood being a scarce resource, transfusion was considered as an alternative over ESA owing to some disadvantages including cost, 4--8 weeks latent period before observing maximum benefit and NCCN guidelines suggesting using ESA only in chemotherapy induced anemia \[[@CR7], [@CR26], [@CR30]\]. Attending physicians, patients' and their family alike, seeking immediate symptomatic improvements in order to avoid lengthier hospital stay to minimize cost, could yet be another reason for practicing blood transfusion over ESA.

In the present study, the mean hemoglobin concentration in anemic cancer palliative patients was found to be 9.03 ± 0.72 g/dL which was again higher than previous studies as hemoglobin cutoff values for transfusion was higher in our study \[[@CR8], [@CR16], [@CR22], [@CR23]\]. Likewise, the average pints transfused in the study was 1.36 ± 0.67, higher than reported in previous studies \[[@CR8], [@CR16]\]. However, 32/46 (69.5%) of patients were transfused with only 1 pint of packed cell which was similar to referenced literatures \[[@CR8], [@CR16]\]. This can again be explained by the low cutoff hemoglobin values.

Mercadante S. et al. reported short-term improvement in fatigue and dyspnea symptoms similar to present study \[[@CR31]\]. Hemoglobin levels above 12 g/dL have shown to improve cancer related fatigue and overall QoL \[[@CR32], [@CR33]\]. Studies have advised appropriate use of packed red cell to treat fatigue symptom rather than treating anemia \[[@CR34]\].Thirty seven percent patients reported improvement in fatigue symptoms similar to Brown E. et al. and Preston NJ. et al. \[[@CR16], [@CR33]\] and 56.4% in breathlessness symptoms. Statistically significant symptomatic improvement of fatigue and breathlessness was observed in both categories of patients (transfused vs. non-transfused). As the post-transfusion data was collected on day 7, the beneficial effect of transfusion beyond the seventh day is inconclusive. In transfused patients, the improvement could have been due to correction of CRF secondary to anemia. Likewise, in patients who were not transfused, the improvement could have been due to medical management and bed rest. Also, tendency of a person seeking attention when sick and hopefulness of being cured on visiting the clinician could be an additional reason for both group of patients. As it is commonly believed, a clinician even on touching or talking to a patient is able to cure 90% of the disease symptoms. This self-psychology of being cured upon consulting a physician could also be a factor of improvement of symptoms in both sets of patients. The present study is not in a condition to postulate the reasons behind the improvement, but one thing that has been demonstrated is the association between packed red cell transfusion and patient-reported fatigue and dyspnea. Previous study by To TH. et al. \[[@CR35]\] using objective-scale measures have failed to show transfusion benefits correlating with subjective responses, though subjective improvement was reported.

Goksu SS et al. \[[@CR36]\] showed survival benefits in palliative patients following transfusion but we did not include survival benefits, nutritional and socioeconomic status as a part of the study.

In the present study, we speculated anemia in palliative patients to be a result of chronic inflammation. Other causes like iron, folic acid and vitamin 12 deficiencies, parasitic infection, acute blood loss were not considered. This could be a limitation of the study. We only took blood transfusion as a reference over ESA. Further studies could be done comparing the beneficial effects of transfusion and ESA. Apart from symptoms of fatigue and breathlessness, other symptoms can also be considered for future research. In this study we did not take into account the diagnosis of the disease, the tumor site, size and grading of the disease. Better results can be obtained by classifying the tumor site and studying beneficial effects of transfusion on different types of cancer patients. Due to the lack of laboratory facilities and cost factor, this study also failed to measure the level of cytokines which is one important factor causing anemia in cancer. Also, we did not consider the chemotherapy regimen used for cancer treatment and its probable effect in anemia was also ignored.

In spite of being a crucial piece of the thread, we failed to report the transfusion reactions in our study. Though no late transfusion reactions were observed, some early transfusion reactions like thrombophlebitis and non-hemolytic febrile reactions was noted.

Conclusion {#Sec5}
==========

Anemia is present in a majority of cancer palliative patients. Symptomatic benefits to CRF and breathlessness secondary to anemia can be achieved by packed red cell transfusion; however transfusion should be customized to an individual patient by an experienced palliative care physician in accordance with patients' preferences. The authors recommend not withholding packed cell transfusion in cancer palliative patients as the study reported no increased risks of adverse events post-transfusion. Larger population studies are to be conducted before arriving to any conclusions.
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